Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia [Phase 2]
A Phase 2 clinical trial is evaluating the safety and efficacy of zanubrutinib for antiphospholipid syndrome with secondary thrombocytopenia…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L. [NA]
The update reports on the interpretability of the Quantra Viscoelastic Test in patients with hematologic malignancies and severe thrombocyto…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia [NA]
A trial evaluating yttrium-90 radioembolization for cirrhosis-associated thrombocytopenia was terminated, and results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-01-10Clinical Trial Update: Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State [NA]
A completed clinical trial evaluating the bioequivalence of eltrombopag olamine tablets under fasting conditions.
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer [Phase 2]
Phase 2 trial evaluating Herombopag to prevent radio-chemotherapy induced thrombocytopenia in cervical cancer; the study status is not yet r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2024-12-02EMA Authorised: Tavlesse (Fostamatinib disodium) — Instituto Grifols S.A.
EMA authorised Tavlesse (fostamatinib disodium) for thrombocytopenia, with Instituto Grifols S.A. as the marketing authorisation holder; dec…
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
A retrospective study examining venous thromboembolism in patients with hematologic cancers and post-hematopoietic cell transplant, focusing…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery [Phase 2]
A Phase 2 clinical trial evaluating the combination of lusutrombopag and recombinant human thrombopoietin for thrombocytopenia in patients w…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure
A clinical trial evaluating avatrombopag for thrombocytopenia in adults with chronic liver disease undergoing a procedure was terminated.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia
This clinical trial update describes an ongoing study evaluating the efficacy and safety of Avatricopal in patients with chronic liver disea…
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT [Phase 2, Phase 3]
Clinical trial update describes ongoing Phase 2/Phase 3 evaluation of avatrombopag for thrombocytopenia after haploidentical hematopoietic s…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Platelet Transfusion in Critically Ill Patients With Thrombocytopenia [Phase 3]
A Phase 3 trial update about platelet transfusion in critically ill patients with thrombocytopenia, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients
Completed evaluation of immunogenicity and thrombotic potential of circulating protamine-heparin complexes in cardiac surgery patients.
-
CLINICAL_TRIALS research · 2024-08-20Clinical Trial Update: Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia [Phase 4]
Phase 4 clinical trial evaluating the efficacy and safety of hetrombopag in preoperative patients with thrombocytopenia is currently recruit…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: TPO-Mimetic Use in Children for Hematopoietic Failure [EARLY_Phase 1]
An early-phase 1 pediatric trial evaluating thrombopoietin mimetics for hematopoietic failure has completed. The study enrolled children wit…
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
Eltrombopag was studied for efficacy and safety in patients with refractory thrombocytopenia associated with connective tissue diseases; the…
-
CLINICAL_TRIALS research · 2024-05-30Clinical Trial Update: Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy [Phase 2]
Phase 2 clinical trial evaluating hetrombopag for thrombocytopenia induced by concurrent chemoradiotherapy; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating recombinant human thrombopoietin (rhTPO) for sepsis patients with acute severe thrombocytopenia is curren…
-
FDA approval · 2024-04-18FDA Approved: ELTROMBOPAG — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic eltrombopag (eltrombopag olamine).
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of herombopag in patients with thrombocytopenia before hepatectomy.
-
EMA approval · 2024-02-16EMA Authorised: Mulpleo (previously Lusutrombopag Shionogi) (Lusutrombopag) — Shionogi B.V.
Mulpleo (lusutrombopag) has been authorised in the EU for thrombocytopenia with Shionogi B.V. as the marketing authorisation holder.
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia [Phase 2]
A Phase 2 trial evaluating fostamatinib alone or with ruxolitinib for myelofibrosis patients with severe thrombocytopenia has been terminate…
-
FDA approval · 2023-11-29FDA Approved: ALVAIZ — Original Application (Teva Pharmaceuticals, Inc.)
ALVAIZ (eltrombopag) from Teva received FDA approval through an original application for the treatment of thrombocytopenia conditions by inc…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP [Phase 2]
Phase 2 trial comparing eltrombopag plus diacerein versus eltrombopag alone in adult thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients [Phase 2]
Phase 2 trial assessing hetrombopag for primary prevention of niraparib-induced thrombocytopenia in advanced ovarian cancer patients; effica…